(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 April 2020 (02.04.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/068832 A1

(51) International Patent Classification:
A61K 31/198 (2006.01) *A61K 9/00* (2006.01)
A61K 31/5415 (2006.01)

(21) International Application Number:
PCT/US2019/052705

(22) International Filing Date:
24 September 2019 (24.09.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/735,997	25 September 2018 (25.09.2018)	US
62/785,602	27 December 2018 (27.12.2018)	US
62/785,605	27 December 2018 (27.12.2018)	US
62/785,606	27 December 2018 (27.12.2018)	US
62/787,614	02 January 2019 (02.01.2019)	US
62/817,274	12 March 2019 (12.03.2019)	US
62/840,539	30 April 2019 (30.04.2019)	US

(71) Applicant: **CHASE THERAPEUTICS CORPORATION** [US/US]; 1825 K Street NW, Suite 510, Washington, District of Columbia 20006 (US).

(72) Inventors: **CHASE, Thomas, N.**; 1825 K Street NW, Suite 510, Washington, District of Columbia 20006 (US). **CLARENCE-SMITH, Kathleen, E.**; 1825 K Street NW, Suite 510, Washington, District of Columbia 20006 (US).

(74) Agent: **PHAN, Tu, A.** et al.; Sughrue Mion PLLC, Suite 900, Washington, District of Columbia 20006-1812 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2020/068832 A1

(54) Title: COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS

(57) Abstract: The present invention provides a pharmaceutical combination comprising an inhibitor of dopamine agonist adverse effects and a dopamine agonist, for treating Parkinson's disease and Parkinson's disease-related disorders.